<?xml version='1.0'?>
<!DOCTYPE art SYSTEM 'http://www.biomedcentral.com/xml/article.dtd'>
<art>
   <ui>1476-0711-3-13</ui>
   <ji>1476-0711</ji>
   <fm>
      <dochead>Research</dochead>
      <bibl>
         <title>
            <p>Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in <it>Enterobacteriaceae</it></p>
         </title>
         <aug>
            <au id="A1" ca="yes">
               <snm>Qin</snm>
               <fnm>Xuan</fnm>
               <insr iid="I1"/>
               <email>xuan.qin@seattlechildrens.org</email>
            </au>
            <au id="A2">
               <snm>Weissman</snm>
               <mi>J</mi>
               <fnm>Scott</fnm>
               <insr iid="I2"/>
               <email>weissman@u.washington.edu</email>
            </au>
            <au id="A3">
               <snm>Chesnut</snm>
               <mnm>Frances</mnm>
               <fnm>Mary</fnm>
               <insr iid="I1"/>
               <email>mary.f.chesnut@us.army.mil</email>
            </au>
            <au id="A4">
               <snm>Zhang</snm>
               <fnm>Bei</fnm>
               <insr iid="I3"/>
               <email>bessiezh@yahoo.com</email>
            </au>
            <au id="A5">
               <snm>Shen</snm>
               <fnm>Lisong</fnm>
               <insr iid="I4"/>
               <email>lshen@public1.sta.net.cn</email>
            </au>
         </aug>
         <insg>
            <ins id="I1">
               <p>Microbiology Laboratory, Department of Laboratories and Pathology, Children's Hospital and Regional Medical Center, Seattle, WA 98105, USA</p>
            </ins>
            <ins id="I2">
               <p>Division of Infectious Disease, Department of Pediatrics</p>
            </ins>
            <ins id="I3">
               <p>Children's Hospital and Regional Medical Center, Seattle, WA 98105, USA</p>
            </ins>
            <ins id="I4">
               <p>Laboratory Diagnostic Center, Xin Hua Hospital and Shanghai Children's Medical Center, Shanghai Second Medical University, Shanghai, China</p>
            </ins>
         </insg>
         <source>Annals of Clinical Microbiology and Antimicrobials</source>
         <issn>1476-0711</issn>
         <pubdate>2004</pubdate>
         <volume>3</volume>
         <issue>1</issue>
         <fpage>13</fpage>
         <url>http://www.ann-clinmicrob.com/content/3/1/13</url>
         <xrefbib>
            <pubidlist>
               <pubid idtype="pmpid">15256000</pubid>
               <pubid idtype="doi">10.1186/1476-0711-3-13</pubid>
            </pubidlist>
         </xrefbib>
      </bibl>
      <history>
         <rec>
            <date>
               <day>23</day>
               <month>3</month>
               <year>2004</year>
            </date>
         </rec>
         <acc>
            <date>
               <day>15</day>
               <month>7</month>
               <year>2004</year>
            </date>
         </acc>
         <pub>
            <date>
               <day>15</day>
               <month>7</month>
               <year>2004</year>
            </date>
         </pub>
      </history>
      <cpyrt>
         <year>2004</year>
         <collab>Qin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</collab>
      </cpyrt>
      <abs>
         <sec>
            <st>
               <p>Abstract</p>
            </st>
            <p>Resistance to <it>&#946;</it>-lactam antibiotics in enteric Gram-negative bacilli may be difficult to detect using standard methods of either Kirby-Bauer disc diffusion (KBDD) or broth dilution for minimal inhibitory concentration (MIC). This difficulty is due to genetic differences in resistance determinants, differences in levels of gene expression, and variation in spectra of enzymatic activity against the substrate <it>&#946;</it>-lactams used for susceptibility testing. We have examined 95 clinical isolates reportedly susceptible to ceftazidime and ceftriaxone, as originally determined by either KBDD or MIC methods. The organisms studied here were isolated in 2002 from two pediatric hospital centers (Seattle, USA and Shanghai, China). They belong to the inducible <it>&#946;</it>-lactamase producing Gram-negative bacilli, such as <it>Enterobacter </it>spp., <it>Citrobacter </it>spp., <it>Serratia </it>spp., <it>Morganella </it>spp., <it>Providencia </it>spp., and <it>Proteus vulgaris</it>. A Kirby-Bauer disc approximation (KBDA) method identified inducible phenotypes of third-generation cephalosporin resistance in 76% of isolates, which would otherwise be considered susceptible by standard KBDD methods.</p>
         </sec>
      </abs>
   </fm>
   <bdy>
      <sec>
         <st>
            <p>Introduction</p>
         </st>
         <p>Nosocomial infections due to antibiotic-resistant, enteric Gram-negative bacilli have increased at an alarming rate in intensive care facilities, and are frequently associated with immunocompromised hosts, for whom they may be particularly devastating <abbrgrp><abbr bid="B1">1</abbr><abbr bid="B2">2</abbr><abbr bid="B3">3</abbr><abbr bid="B4">4</abbr><abbr bid="B5">5</abbr></abbrgrp>. Multidrug-resistant <it>Escherichia coli </it>and <it>Klebsiella </it>spp. (as well as other <it>Enterobacteriaceae</it>) carrying plasmid-borne extended-spectrum <it>&#946;</it>-lactamases (ESBLs) have attracted much interest among clinical microbiologists, infectious disease specialists, and infection control practitioners <abbrgrp><abbr bid="B6">6</abbr><abbr bid="B7">7</abbr><abbr bid="B8">8</abbr></abbrgrp>. In contrast, the carriage of chromosomally encoded AmpC <it>&#946;</it>-lactamases by these organisms has been deemed a commensal trait of uncertain consequence, and thus the management of such infections has not benefited from the multidisciplinary approach taken with ESBL infections <abbrgrp><abbr bid="B9">9</abbr><abbr bid="B10">10</abbr><abbr bid="B11">11</abbr><abbr bid="B12">12</abbr></abbrgrp>.</p>
         <p>Standard Kirby-Bauer disc diffusion (KBDD) methods and automated minimal inhibitory concentration (MIC) instruments used in most clinical laboratories do not readily detect <it>ampC</it>-type of inducible resistance. Therapy based on such susceptible reports may result in selection of resistance <it>in vivo </it><abbrgrp><abbr bid="B9">9</abbr><abbr bid="B10">10</abbr><abbr bid="B11">11</abbr><abbr bid="B12">12</abbr><abbr bid="B13">13</abbr></abbrgrp>. A few instructive studies have reported that the observation of increased MICs to third-generation cephalosporins using high-density inocula (increasing sensitivity for detection of derepressed mutant subpopulations) may be used to predict clinical failures <abbrgrp><abbr bid="B14">14</abbr><abbr bid="B15">15</abbr></abbrgrp>. To address this gap, the National Committee for Clinical Laboratory Standards (NCCLS) has included warnings such as '<it>Enterobacter</it>, <it>Citrobacter</it>, and <it>Serratia </it>spp. may develop resistance during prolonged therapy with third generation cephalosporins' in its interpretive guideline publications <abbrgrp><abbr bid="B16">16</abbr></abbrgrp>. However, methods that can be used to detect such resistance have not been suggested.</p>
         <p>In this study, we used the Kirby-Bauer disc approximation (KBDA) method <abbrgrp><abbr bid="B17">17</abbr><abbr bid="B18">18</abbr><abbr bid="B19">19</abbr></abbrgrp> to detect and characterize several phenotypes of inducible <it>&#946;</it>-lactamase production. The interpretation of antibiotic susceptibilities was based on a combination of inhibitary zone sizes and zone morphologies near a potent agent of <it>&#946;</it>-lactamase induction.</p>
      </sec>
      <sec>
         <st>
            <p>Materials and methods</p>
         </st>
         <sec>
            <st>
               <p>Bacterial isolates and testing conditions</p>
            </st>
            <p>The 95 clinical isolates of <it>Enterobacter</it>, <it>Citrobacter</it>, <it>Serratia</it>, <it>Morganella</it>, <it>Providencia</it>, and <it>Proteus vulgaris </it>examined in this study were considered etiologic agents in cases of meningitis, bacteremia, pneumonia, wound, and urinary tract infections. Of the 95 strains tested, 56 were recovered during the fourth quarter of 2002 at Children's Hospital and Regional Medical Center (CHRMC) in Seattle, WA, and 39 were recovered during 2002 at Shanghai Children's Medical Center (SCMC), a sister hospital in Shanghai, China. When initially tested by standard KBDD and/or Vitek MIC methods, these isolates were interpreted as susceptible to third-generation cephalosporins (i.e., ceftazidime and ceftriaxone), based on NCCLS criteria <abbrgrp><abbr bid="B16">16</abbr></abbrgrp>. In addition, control strains of <it>Escherichia coli </it>ATCC 25922 and a cephalosporin-resistant <it>E. cloacae </it>strain A (as shown in fig. <figr fid="F1">1f</figr>) were included in the study.</p>
            <fig id="F1">
               <title>
                  <p>Figure 1</p>
               </title>
               <caption>
                  <p>Types of zones of inhibition determined by KBDA method</p>
               </caption>
               <text>
                  <p>Types of zones of inhibition determined by KBDA method. With FOX discs in the center, CTX discs are placed 15 mm to the left of FOX, while CAZ discs are 15 mm to the right of FOX as shown in fig 1a. (a) Susceptible zone: no growth between FOX and CTX/CAZ, <it>E. cloacae </it>02212. (b) S<it>l </it>zone: slight growth between FOX and CTX/CAZ, <it>E. agglomerans </it>02039. (c) C zone: CTX zone distortion near FOX, <it>S. marcescens </it>02319. (d) C zone: CTX zone distortion near FOX. <it>M. morganii </it>02325. (e) D zone: CTX and CAZ zone truncation near FOX, <it>E. aerogenes </it>02324. (f) Resistant zone: no zone of inhibition around any disc, <it>E. cloacae </it>strain A.</p>
               </text>
               <graphic file="1476-0711-3-13-1"/>
            </fig>
            <p>Testing conditions featured standard KB discs (Becton Dickinson Microbiology Systems, BBL, Sparks, MD, for CHRMC; Oxoid Limited, Basingstoke, Hampshire, England, for SCMC) and Mueller Hinton agar plates (BBL) with 35&#176;C overnight incubation (~16 hours) in ambient air for KBDA analysis (NCCLS M2-A7) <abbrgrp><abbr bid="B20">20</abbr></abbrgrp>. Standard 0.5 McFarland saline suspensions of bacteria were used to inoculate the Mueller Hinton agar media confluently with a cotton swab. The resultant zones of inhibition were measured with a caliper using transmitted light. We determined the diameter of circular zones of inhibition and the shortest radius of inducer-blunted zones.</p>
         </sec>
         <sec>
            <st>
               <p>KBDA for detection of third-generation cephalosporin resistance</p>
            </st>
            <p>The disc approximation technique was used as previously described <abbrgrp><abbr bid="B17">17</abbr></abbrgrp> to detect inducible resistance to third-generation cephalosporins. We used cefoxitin (FOX) as a <it>&#946;</it>-lactamase induction agent, and cefotaxime (CTX) and ceftazidime (CAZ) as the third-generation cephalosporin reporter agents <abbrgrp><abbr bid="B18">18</abbr><abbr bid="B19">19</abbr><abbr bid="B21">21</abbr></abbrgrp>. Cefepime (FEP) was used for fourth-generation cephalosporin susceptibility testing. Based on preliminary results (described below), we selected a 15-mm edge-to-edge distance between the discs for <it>&#946;</it>-lactamase induction testing of all isolates in the study. We also reviewed the initial susceptibility results of the 95 isolates to gentamicin (GM) and ciprofloxacin (CIP). To determine CAZ and CTX inhibitory activities upon induction, we doubled the radius measurements of zones of inhibition in the direction of the FOX discs, for direct comparison with the diameters of unaffected zones. Median zone measurement values were analyzed using the Wilcoxon signed-ranks test.</p>
         </sec>
      </sec>
      <sec>
         <st>
            <p>Results</p>
         </st>
         <sec>
            <st>
               <p>Determination of disc distance for KBDA and measurements of antibiotic zones of inhibition</p>
            </st>
            <p>A pilot KBDA test was carried out with 13 strains of enteric Gram-negative bacilli, including <it>E. coli </it>ATCC 25922, <it>C. freundii </it>(n = 3), <it>E. aerogenes </it>(n = 1), <it>E. agglomerans </it>(also known as <it>Pantoae agglomerans</it>, n = 2), <it>E. cloacae </it>(n = 3), <it>P. rettgeri </it>(n = 1), and <it>S. marcescens </it>(n = 2). For each strain, we placed a FOX disc in the center and approximated CTX and CAZ discs on each side, comparing zones of inhibition for edge-to-edge distances of 15, 20, and 25 mm. FOX showed no effect on CTX nor CAZ susceptibilities in <it>E. coli </it>ATCC 25922, the <it>E. agglomerans</it>, and the <it>P. rettgeri </it>at any given disc distance. The most easily discernable patterns of FOX induced zone distortions were observed using the 15-mm disc distance in the remaining organisms.</p>
            <p>We then tested each of 95 isolates against paired antibiotics using the 15-mm testing method. The test was repeated at least once with each organism. Averages of the zone measurements were used for final analysis. In the absence of FOX influence, the median zone sizes (and ranges) for CAZ and CTX were 27 mm (20&#8211;34 mm) and 29 mm (23&#8211;34 mm), respectively. With FOX induction, the radius from the center of the disc to the distorted zone edge near FOX ranged from 8 to 15 mm for CAZ and 8 to 16 mm for CTX, corresponding to median zone diameters of 23 mm and 24 mm for CAZ and CTX, respectively. For both CAZ and CTX, the FOX-induced zones were significantly smaller (<it>p </it>&lt;0.0001) than the uninduced zones.</p>
         </sec>
         <sec>
            <st>
               <p>Interpretation of drug susceptibility patterns</p>
            </st>
            <p>Based on patterns of zone distortion, five types of susceptibility could be readily recognized among the test results. The five patterns (or zone morphologies) reflect incremental, visually discernable levels of bacterial resistance to CTX and CAZ, due to varying degrees of <it>ampC </it>induction (fig. <figr fid="F1">1a,1b,1c,1d,1e,1f</figr>). The two "extreme" patterns of drug susceptibility (fig. <figr fid="F1">1a</figr> and <figr fid="F1">1f</figr>) may be easily interpreted as drug-sensitive and drug-resistant, respectively. Resistant ('R') strains had no zones of inhibition around any of the three discs (fig. <figr fid="F1">1f</figr>, a CTX-resistant control <it>E. cloacae </it>strain A), while susceptible ('S') strains exhibited zones of inhibition above break points for CTX (&#8805; 23 mm) and CAZ (&#8805; 18 mm) and no growth between CTX-FOX or CAZ-FOX pairs (shown by <it>E. cloacae </it>02212 in fig. <figr fid="F1">1a</figr>). Fifteen organisms were classified as susceptible to CTX and CAZ by the KBDA method: <it>C. freundii </it>(n = 1), <it>C. koseri </it>(n = 4), <it>E. agglomerans </it>(n = 2), <it>E. amnigenus </it>(n = 2), <it>E. asburiae </it>(n = 1), <it>E. cloacae </it>(n = 3), <it>P. rettgeri </it>(n = 1), and <it>S. liquefaciens </it>(n = 1).</p>
            <p>However, not all patterns of inhibition could be judged solely by zone size measurement and thus interpreted using standard NCCLS guidelines. Hence, we distinguished three additional patterns, based on type of zone morphology around CTX (or CAZ) next to FOX and on bacterial growth between the disc pairs. 1) <ul>Sl</ul>ight growth ('S<it>l</it>'-type zones) near FOX, but no identifiable zone distortion around CTX or CAZ (fig. <figr fid="F1">1b</figr>), was observed for 8 isolates: <it>E. agglomerans </it>(n = 5), <it>E. sakazakii </it>(n = 2), and <it>P. vulgaris </it>(n = 1). All exhibited zones of inhibition above the breakpoints for CTX and CAZ, and were thus interpreted as susceptible to these agents. 2) Zones of inhibition shaped like the letter 'C' ('C'-type zones), with bacterial growth pressing towards CTX or CAZ as a result of FOX induction (fig. <figr fid="F1">1c,1d</figr>), were observed (n = 23). Although the inducible growth was partially cleared by inhibitory action of FOX, producing letter 'C'-shaped zones, distortions of circular zones of inhibition around CTX were apparent. 3) Zones of inhibition resembling the letter 'D' ('D'-type zones), due to a flat edge of growth on both sides of FOX pressing against CTX and CAZ (fig. <figr fid="F1">1e</figr>), were also observed (n = 49). Because C- and D-types of growth around CTX and CAZ were clearly influenced by the close proximity of FOX, known for its potent effect on <it>ampC </it>induction, we have classified strains exhibiting such resistance patterns as 'Resistant (Inducible)'. Table <tblr tid="T1">1</tblr> summarizes KBDA testing results for all 95 isolates, grouped into S-, S<it>l</it>-, C- and D-types of zone categories. By classifying as 'susceptible' only those strains exhibiting S- and S<it>l</it>-type growth patterns by the KBDA method, we have identified inducible resistance phenotypes in 76% (72/95) of the study isolates that were all reportedly susceptible to third-generation cephalosporins by standard KBDD or MIC methods. Inducible CTX resistance occurred in 80% (45/56) of CHRMC isolates and 69% (27/39) of SCMC isolates. The resistance patterns are not directly comparable due to differences in species distribution between the two groups. In figure <figr fid="F2">2</figr>, we summarize CTX susceptibility data generated by the KBDA method, by species. The same KBDA method was also employed to examine FEP susceptibility under the induction of FOX in all 95 isolates. FOX induction had minimal effect on the size or shapes of FEP zones of inhibition against this group of isolates (data not shown).</p>
            <fig id="F2">
               <title>
                  <p>Figure 2</p>
               </title>
               <caption>
                  <p>Distribution of inducible resistance detected by KBDA among bacterial genera and species</p>
               </caption>
               <text>
                  <p>Distribution of inducible resistance detected by KBDA among bacterial genera and species.</p>
               </text>
               <graphic file="1476-0711-3-13-2"/>
            </fig>
            <tbl id="T1">
               <title>
                  <p>Table 1</p>
               </title>
               <caption>
                  <p>Types of zones of inhibition around CTX determined by KBDA.</p>
               </caption>
               <tblbdy cols="4">
                  <r>
                     <c ca="center">
                        <p>KBDA zone types around CTX</p>
                     </c>
                     <c ca="center">
                        <p>No. organisms (n = 95)</p>
                     </c>
                     <c ca="center">
                        <p>Percentage of the zone type</p>
                     </c>
                     <c ca="center">
                        <p>Susceptibility interpretation</p>
                     </c>
                  </r>
                  <r>
                     <c cspan="4">
                        <hr/>
                     </c>
                  </r>
                  <r>
                     <c ca="center">
                        <p>S-type</p>
                     </c>
                     <c ca="center">
                        <p>15</p>
                     </c>
                     <c ca="center">
                        <p>16%</p>
                     </c>
                     <c ca="center">
                        <p>Susceptible 24%</p>
                     </c>
                  </r>
                  <r>
                     <c ca="center">
                        <p>S<it>l</it>-type</p>
                     </c>
                     <c ca="center">
                        <p>8</p>
                     </c>
                     <c ca="center">
                        <p>8%</p>
                     </c>
                     <c>
                        <p/>
                     </c>
                  </r>
                  <r>
                     <c ca="center">
                        <p>C-type</p>
                     </c>
                     <c ca="center">
                        <p>23</p>
                     </c>
                     <c ca="center">
                        <p>24%</p>
                     </c>
                     <c ca="center">
                        <p>Resistant (Inducible) 76%</p>
                     </c>
                  </r>
                  <r>
                     <c ca="center">
                        <p>D-type</p>
                     </c>
                     <c ca="center">
                        <p>49</p>
                     </c>
                     <c ca="center">
                        <p>52%</p>
                     </c>
                     <c>
                        <p/>
                     </c>
                  </r>
               </tblbdy>
            </tbl>
         </sec>
      </sec>
      <sec>
         <st>
            <p>Discussion</p>
         </st>
         <p>Although <it>in vitro </it>susceptibility testing remains the cornerstone of clinical antibacterial therapy, not all naturally occurring mechanisms of resistance can be detected by standard laboratory methodologies <abbrgrp><abbr bid="B14">14</abbr></abbrgrp>. Over 15 years ago, Sanders <it>et al. </it><abbrgrp><abbr bid="B10">10</abbr><abbr bid="B11">11</abbr></abbrgrp> reported the emergence of bacterial resistance during cephalosporin treatment occurred in some 20&#8211;40% of systemic infections with these Gram-negative bacilli, accounting for treatment failure or relapse in at least 10% of such cases. Yet in the intervening years, individual hospital antibiograms have reported 75&#8211;90% of <it>E. cloacae </it>and <it>S. marcescens </it>isolates to be susceptible to third-generation cephalosporins. Thus, without accurate laboratory detection and informative reporting of such occult resistance phenotypes, the treatment of Gram-negative infections may remain suboptimal.</p>
         <p>Of 95 isolates reported 'susceptible' to CTX and CAZ by conventional KBDD testing, 72 isolates (76%) exhibited C- and D-type inducible AmpC resistance. Moreover, the rates of resistance among this representative sample of common pathogens were rather alarming. Of the <it>E. cloacae </it>isolates, representing nearly 30% of the study strains, we found inducible resistance as high as 90% (fig. <figr fid="F2">2</figr>). Likewise, <it>E. aerogenes</it>, <it>S. marcescens</it>, and <it>C. freundii</it>, together accounting for 27% of study strains, exhibited a combined inducible resistance rate of 94%. This type of occult resistance phenotype may be missed by the standard testing methods and may have contributed to the frequency of treatment failures previously observed <abbrgrp><abbr bid="B9">9</abbr><abbr bid="B10">10</abbr><abbr bid="B11">11</abbr><abbr bid="B12">12</abbr><abbr bid="B13">13</abbr></abbrgrp>.</p>
         <p>Distorted patterns of antibiotic zones of inhibition in the presence of <it>&#946;</it>-lactamase induction agent FOX may provide clinical microbiologists with information not evident from conventional interpretations of zone size for this group of Gram-negative bacilli <abbrgrp><abbr bid="B18">18</abbr></abbrgrp>. The statistical significance of the zone sizes between CTX and CTX-next-to-FOX strongly supports the notion of incorporating zone morphology into interpretation of antibiotic susceptibility results. We consider both 'C' and 'D' zone morphologies to be indicative of inducible resistance, and thus intend to categorize isolates exhibiting 'C' and 'D' zones as potentially resistant to third-generation cephalosporins. One potential strategy for communicating such data to clinicians would be to introduce a dual descriptor (such as 'S/R') to encompass results of both conventional and KBDA methods; a second level interpretation (such as 'Susceptibility testing indicates that resistance to this agent may emerge during prolonged therapy; this agent may still be useful for treatment of uncomplicated infections of the urinary tract, where high drug concentrations can be achieved') would accompany this descriptor <abbrgrp><abbr bid="B16">16</abbr><abbr bid="B22">22</abbr><abbr bid="B23">23</abbr></abbrgrp>.</p>
         <p>The variety of zone phenotypes generated by KBDA may provide some insight into the regulation of these important genetic determinants. The distinctive zone morphologies observed among study strains may be indicative of the action of an auxiliary regulatory gene(s), such as <it>ampR </it>and <it>ampD</it>, on <it>ampC </it>expression rather than, for instance, point mutations in <it>ampC </it>promoters or regulators <abbrgrp><abbr bid="B24">24</abbr><abbr bid="B25">25</abbr><abbr bid="B26">26</abbr><abbr bid="B27">27</abbr></abbrgrp>. In contrast, the unmistakable no-zone type of AmpC resistance (a control strain shown in fig. <figr fid="F1">1f</figr>) is associated with permanent <it>ampC </it>derepression typically caused by promoter point mutations <abbrgrp><abbr bid="B28">28</abbr></abbrgrp> or mutations in regulatory genes <it>ampD </it>or <it>ampR </it><abbrgrp><abbr bid="B29">29</abbr></abbrgrp>. Historically designated as <it>de novo </it>resistance, this phenotype would not be missed by conventional MIC and KBDD methods.</p>
         <p>Consistent with previous findings, third-generation cephalosporin resistance conferred by <it>ampC </it>induction did not predict FEP resistance in this group of Gram-negative bacilli <abbrgrp><abbr bid="B30">30</abbr><abbr bid="B31">31</abbr></abbrgrp>. Many clinical isolates exhibiting inducible CTX and/or CAZ resistance in this collection remained susceptible to the fourth-generation cephalosporin FEP; those isolates resistant to FEP may have utilized a distinct mechanism, such as blockage of drug uptake <abbrgrp><abbr bid="B32">32</abbr><abbr bid="B33">33</abbr></abbrgrp>, to escape its antibacterial activity. In the treatment of invasive infections caused by such pathogens, continued efficacy of alternative or combination therapy is supported by GM or CIP susceptibility at CHRMC <abbrgrp><abbr bid="B34">34</abbr></abbrgrp>. Of interest, all 7 organisms resistant to these agents (5 strains resistant to GM and 2 resistant to CIP) were isolated from SCMC. No conclusive statements, however, can be made regarding the comparative rates of drug resistance between the two institutions due to differing bacterial genus and species make-up of the two collections.</p>
         <p>The extent to which generalized treatment recommendations can be based solely on isolation of so-called SPICE-MP (<it>Serratia</it>, <it>Proteus </it>spp. &#8211; Indole positive,<it>Citrobacter</it>, <it>Enterobacter</it>, <it>Morganella</it>, and <it>Providencia</it>) organisms, the 'usual suspects' for <it>ampC </it>carriage, remains limited <abbrgrp><abbr bid="B22">22</abbr><abbr bid="B23">23</abbr></abbrgrp>. Those 23 (24%) isolates that did not exhibit recognizable zone distortion patterns were considered susceptible to CTX by KBDA, although some or all may contain a similar array of <it>ampC </it>determinants to the strains that exhibited resistant patterns. Of the AmpC family of <it>&#946;</it>-lactamases, the spectrum of activity witnessed in our study isolates encompasses at least three Bush groups: group 1 for the majority, but group 2b for <it>C. koseri </it>and group 2e for <it>P. vulgaris </it><abbrgrp><abbr bid="B35">35</abbr></abbrgrp>. Thus, the genetics of both the structural <it>ampC </it>sequences and their regulatory pathways may still be highly polymorphic. In addition, organisms hosting both ESBL and <it>amp</it>C determinants have been found in many enteric Gram-negative bacilli <abbrgrp><abbr bid="B6">6</abbr><abbr bid="B36">36</abbr></abbrgrp>, compounding the difficulties in recognition and detection. In short, accurate species identification does not allow simple assignment of the isolates to either ESBL- or AmpC-like <it>&#946;</it>-lactam susceptibility patterns.</p>
         <p>This study supports the use of a modified KBDD method, which would provide simple, visual information about bacterial resistance phenotypes. Further characterization of KBDA zone morphologies, considered jointly with zone size measurement, can be used to detect phenomena that even a refined quantitative system would be unable to measure. Laboratory tools need to be developed, protocols standardized and guidelines established to provide accurate detection and reporting practices that will enable more effective treatment strategies for these difficult infections.</p>
      </sec>
   </bdy>
   <bm>
      <ack>
         <sec>
            <st>
               <p>Acknowledgements</p>
            </st>
            <p>This study was supported by Department of Laboratories and Pathology, Children's Hospital and Regional Medical Center, Seattle, USA. This work is also a collaborative effort between two pediatric hospitals (CHRMC and SCMC) through International Health Education, Project HOPE (Health Opportunities for People Everywhere). We thank Treva Tsosie for data organization and Excel presentation. We thank Drs. Carla R. Clausen, Marie B. Coyle, and Joe Rutledge for their critical reviews of the manuscript.</p>
         </sec>
      </ack>
      <refgrp>
         <bibl id="B1">
            <title>
               <p>Occurrence and transferability of beta-lactam resistance in <it>Enterobacteriaceae </it>isolated in Children's University Hospital in Bratislava</p>
            </title>
            <aug>
               <au>
                  <snm>Bujdakova</snm>
                  <fnm>H</fnm>
               </au>
               <au>
                  <snm>Hanzen</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Jankovicova</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Klimackova</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Moravcikova</snm>
                  <fnm>M</fnm>
               </au>
               <au>
                  <snm>Milosovic</snm>
                  <fnm>P</fnm>
               </au>
               <au>
                  <snm>Michalkova-Papajova</snm>
                  <fnm>D</fnm>
               </au>
               <au>
                  <snm>Kallova</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Jakab</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Kettner</snm>
                  <fnm>M</fnm>
               </au>
            </aug>
            <source>Folia Microbiol (Praha)</source>
            <pubdate>2001</pubdate>
            <volume>46</volume>
            <fpage>339</fpage>
            <lpage>44</lpage>
            <xrefbib>
               <pubid idtype="pmpid">11830947</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B2">
            <title>
               <p>Antimicrobial susceptibility of respiratory isolates of <it>Enterobacteriaceae </it>and <it>Staphylococcus aureus </it>in Italy: incidence and trends over the period 1997&#8211;1999</p>
            </title>
            <aug>
               <au>
                  <snm>Fontana</snm>
                  <fnm>R</fnm>
               </au>
               <au>
                  <snm>Lo Cascio</snm>
                  <fnm>G</fnm>
               </au>
               <au>
                  <snm>Ligozzi</snm>
                  <fnm>M</fnm>
               </au>
               <au>
                  <snm>Friscia</snm>
                  <fnm>O</fnm>
               </au>
               <au>
                  <snm>Oldoni</snm>
                  <fnm>T</fnm>
               </au>
            </aug>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <pubdate>2001</pubdate>
            <volume>20</volume>
            <fpage>854</fpage>
            <lpage>63</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1007/s100960100628</pubid>
                  <pubid idtype="pmpid" link="fulltext">11837636</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B3">
            <title>
               <p>High frequency of antibiotic resistance among Gram-negative isolates in intensive care units at 10 Swedish hospitals</p>
            </title>
            <aug>
               <au>
                  <snm>Hanberger</snm>
                  <fnm>H</fnm>
               </au>
               <au>
                  <snm>Nilsson</snm>
                  <fnm>LE</fnm>
               </au>
               <au>
                  <cnm>Swedish Study Group</cnm>
               </au>
            </aug>
            <source>Clin Microbiol Infect</source>
            <pubdate>1997</pubdate>
            <volume>3</volume>
            <fpage>208</fpage>
            <lpage>215</lpage>
            <xrefbib>
               <pubid idtype="pmpid">11864106</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B4">
            <title>
               <p>In vitro efficacy of six cephalosporins tested against <it>Enterobacteriacea </it>e isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997&#8211;1998</p>
            </title>
            <aug>
               <au>
                  <snm>Jones</snm>
                  <fnm>RN</fnm>
               </au>
               <au>
                  <snm>Jenkins</snm>
                  <fnm>SG</fnm>
               </au>
               <au>
                  <snm>Hoban</snm>
                  <fnm>DJ</fnm>
               </au>
               <au>
                  <snm>Pfaller</snm>
                  <fnm>MA</fnm>
               </au>
               <au>
                  <snm>Ramphal</snm>
                  <fnm>R</fnm>
               </au>
            </aug>
            <source>Int J Antimicrob Agents</source>
            <pubdate>2000</pubdate>
            <volume>15</volume>
            <fpage>111</fpage>
            <lpage>8</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0924-8579(00)00152-7</pubid>
                  <pubid idtype="pmpid" link="fulltext">10854806</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B5">
            <title>
               <p>Antimicrobial susceptibility of inducible AmpC beta-lactamase-producing <it>Enterobacteriaceae </it>from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Programme, Europe 1997&#8211;2000</p>
            </title>
            <aug>
               <au>
                  <snm>Pfaller</snm>
                  <fnm>MA</fnm>
               </au>
               <au>
                  <snm>Jones</snm>
                  <fnm>RN</fnm>
               </au>
            </aug>
            <source>Int J Antimicrob Agents</source>
            <pubdate>2002</pubdate>
            <volume>19</volume>
            <fpage>383</fpage>
            <lpage>8</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0924-8579(02)00009-2</pubid>
                  <pubid idtype="pmpid" link="fulltext">12007846</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B6">
            <title>
               <p>Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat</p>
            </title>
            <aug>
               <au>
                  <snm>Bradford</snm>
                  <fnm>PA</fnm>
               </au>
            </aug>
            <source>Clin Microbiol Rev</source>
            <pubdate>2001</pubdate>
            <volume>14</volume>
            <fpage>933</fpage>
            <lpage>51</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1128/CMR.14.4.933-951.2001</pubid>
                  <pubid idtype="pmpid" link="fulltext">11585791</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B7">
            <title>
               <p>Laboratory capacity to detect antimicrobial resistance, 1998</p>
            </title>
            <source>MMWR Morb Mortal Wkly Rep</source>
            <volume>48</volume>
            <issue>51&#8211;52</issue>
            <fpage>1167</fpage>
            <lpage>71</lpage>
            <note>2000, Jan 7</note>
         </bibl>
         <bibl id="B8">
            <title>
               <p>Characterization of clinical isolates of <it>Klebsiella pneumoniae </it>from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods</p>
            </title>
            <aug>
               <au>
                  <snm>Steward</snm>
                  <fnm>CD</fnm>
               </au>
               <au>
                  <snm>Rasheed</snm>
                  <fnm>JK</fnm>
               </au>
               <au>
                  <snm>Hubert</snm>
                  <fnm>SK</fnm>
               </au>
               <au>
                  <snm>Biddle</snm>
                  <fnm>JW</fnm>
               </au>
               <au>
                  <snm>Raney</snm>
                  <fnm>PM</fnm>
               </au>
               <au>
                  <snm>Anderson</snm>
                  <fnm>GJ</fnm>
               </au>
               <au>
                  <snm>Williams</snm>
                  <fnm>PP</fnm>
               </au>
               <au>
                  <snm>Brittain</snm>
                  <fnm>KL</fnm>
               </au>
               <au>
                  <snm>Oliver</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>McGowan</snm>
                  <fnm>JE</fnm>
                  <suf>Jr</suf>
               </au>
               <au>
                  <snm>Tenover</snm>
                  <fnm>FC</fnm>
               </au>
            </aug>
            <source>J Clin Microbiol</source>
            <pubdate>2001</pubdate>
            <volume>39</volume>
            <fpage>2864</fpage>
            <lpage>72</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1128/JCM.39.8.2864-2872.2001</pubid>
                  <pubid idtype="pmpid" link="fulltext">11474005</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B9">
            <title>
               <p>Emergence of resistant bacterial strains during treatment of infections in the respiratory tract</p>
            </title>
            <aug>
               <au>
                  <snm>Kosmidis</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Koratzanis</snm>
                  <fnm>G</fnm>
               </au>
            </aug>
            <source>Scand J Infect Dis Suppl</source>
            <pubdate>1986</pubdate>
            <volume>49</volume>
            <fpage>135</fpage>
            <lpage>9</lpage>
            <xrefbib>
               <pubid idtype="pmpid">3103208</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B10">
            <title>
               <p>Inducible beta-lactamases: clinical and epidemiologic implications for use of newer cephalosporins</p>
            </title>
            <aug>
               <au>
                  <snm>Sanders</snm>
                  <fnm>WE</fnm>
                  <suf>Jr</suf>
               </au>
               <au>
                  <snm>Sanders</snm>
                  <fnm>CC</fnm>
               </au>
            </aug>
            <source>Rev Infect Dis</source>
            <pubdate>1988</pubdate>
            <volume>10</volume>
            <fpage>830</fpage>
            <lpage>8</lpage>
            <xrefbib>
               <pubid idtype="pmpid">3055176</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B11">
            <title>
               <p>beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact</p>
            </title>
            <aug>
               <au>
                  <snm>Sanders</snm>
                  <fnm>CC</fnm>
               </au>
               <au>
                  <snm>Sanders</snm>
                  <fnm>WE</fnm>
                  <suf>Jr</suf>
               </au>
            </aug>
            <source>Clin Infect Dis</source>
            <pubdate>1992</pubdate>
            <volume>15</volume>
            <fpage>824</fpage>
            <lpage>39</lpage>
            <xrefbib>
               <pubid idtype="pmpid">1445981</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B12">
            <title>
               <p>Emergence of antimicrobial resistance in gram-negative bacilli causing bacteremia during therapy</p>
            </title>
            <aug>
               <au>
                  <snm>Siebert</snm>
                  <fnm>JD</fnm>
               </au>
               <au>
                  <snm>Thomson</snm>
                  <fnm>RB</fnm>
                  <suf>Jr</suf>
               </au>
               <au>
                  <snm>Tan</snm>
                  <fnm>JS</fnm>
               </au>
               <au>
                  <snm>Gerson</snm>
                  <fnm>LW</fnm>
               </au>
            </aug>
            <source>Am J Clin Pathol</source>
            <pubdate>1993</pubdate>
            <volume>100</volume>
            <fpage>47</fpage>
            <lpage>51</lpage>
            <xrefbib>
               <pubid idtype="pmpid">8346736</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B13">
            <title>
               <p>Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies</p>
            </title>
            <aug>
               <au>
                  <snm>Fish</snm>
                  <fnm>DN</fnm>
               </au>
               <au>
                  <snm>Piscitelli</snm>
                  <fnm>SC</fnm>
               </au>
               <au>
                  <snm>Danziger</snm>
                  <fnm>LH</fnm>
               </au>
            </aug>
            <source>Pharmacotherapy</source>
            <pubdate>1995</pubdate>
            <volume>15</volume>
            <fpage>279</fpage>
            <lpage>91</lpage>
            <xrefbib>
               <pubid idtype="pmpid">7667163</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B14">
            <title>
               <p>beta-Lactamases: quantity and resistance</p>
            </title>
            <aug>
               <au>
                  <snm>Livermore</snm>
                  <fnm>DM</fnm>
               </au>
            </aug>
            <source>Clin Microbiol Infect</source>
            <pubdate>1997</pubdate>
            <volume>3</volume>
            <issue>Suppl 4</issue>
            <fpage>S10</fpage>
            <lpage>S19</lpage>
            <xrefbib>
               <pubid idtype="pmpid">11869238</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B15">
            <title>
               <p>Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing <it>Enterobacteriaceae</it></p>
            </title>
            <aug>
               <au>
                  <snm>Thomson</snm>
                  <fnm>KS</fnm>
               </au>
               <au>
                  <snm>Moland</snm>
                  <fnm>ES</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>2001</pubdate>
            <volume>45</volume>
            <fpage>3548</fpage>
            <lpage>54</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1128/AAC.45.12.3548-3554.2001</pubid>
                  <pubid idtype="pmpid" link="fulltext">11709338</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B16">
            <title>
               <p>National Committee for Clinical Laboratory Standards. 1999, 2000, 2001, 2002, 2003. Performance Standards for Antimicrobial Susceptibility Testing. M100-S8, -S9, S10, S11, S-12, S13</p>
            </title>
            <source>National Committee for Clinical Laboratory Standards, Wayne, PA</source>
         </bibl>
         <bibl id="B17">
            <title>
               <p>Antimicrobial combinations</p>
            </title>
            <aug>
               <au>
                  <snm>Eliopoulos</snm>
                  <fnm>GM</fnm>
               </au>
               <au>
                  <snm>Moellering</snm>
                  <fnm>RC</fnm>
                  <suf>Jr</suf>
               </au>
            </aug>
            <source>In Antibiotics in laboratory Medicine</source>
            <publisher>Williams &amp; Wilkins</publisher>
            <editor>Victor Lorian</editor>
            <edition>4</edition>
            <pubdate>1996</pubdate>
            <fpage>330</fpage>
            <lpage>396</lpage>
         </bibl>
         <bibl id="B18">
            <title>
               <p>Detection of beta-lactamase-mediated resistance</p>
            </title>
            <aug>
               <au>
                  <snm>Livermore</snm>
                  <fnm>DM</fnm>
               </au>
               <au>
                  <snm>Brown</snm>
                  <fnm>DF</fnm>
               </au>
            </aug>
            <source>J Antimicrob Chemother</source>
            <pubdate>2001</pubdate>
            <volume>48</volume>
            <issue>Suppl 1</issue>
            <fpage>59</fpage>
            <lpage>64</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">11420337</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B19">
            <title>
               <p>In vitro antagonism of beta-lactam antibiotics by cefoxitin</p>
            </title>
            <aug>
               <au>
                  <snm>Sanders</snm>
                  <fnm>CC</fnm>
               </au>
               <au>
                  <snm>Sanders</snm>
                  <fnm>WE</fnm>
                  <suf>Jr</suf>
               </au>
               <au>
                  <snm>Goering</snm>
                  <fnm>RV</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>1982</pubdate>
            <volume>21</volume>
            <fpage>968</fpage>
            <lpage>75</lpage>
            <xrefbib>
               <pubid idtype="pmpid">6981376</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B20">
            <title>
               <p>National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Tests; Approved Standard &#8211; Seventh Edition M2-A7</p>
            </title>
            <source>National Committee for Clinical Laboratory Standards, Wayne, PA</source>
            <pubdate>2000</pubdate>
         </bibl>
         <bibl id="B21">
            <title>
               <p>A novel type of AmpC beta-lactamase, ACC-1, produced by a <it>Klebsiella pneumoniae </it>strain causing nosocomial pneumonia</p>
            </title>
            <aug>
               <au>
                  <snm>Bauernfeind</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Schneider</snm>
                  <fnm>I</fnm>
               </au>
               <au>
                  <snm>Jungwirth</snm>
                  <fnm>R</fnm>
               </au>
               <au>
                  <snm>Sahly</snm>
                  <fnm>H</fnm>
               </au>
               <au>
                  <snm>Ullmann</snm>
                  <fnm>U</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>1999</pubdate>
            <volume>43</volume>
            <fpage>1924</fpage>
            <lpage>31</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">10428914</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B22">
            <title>
               <p>Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?</p>
            </title>
            <aug>
               <au>
                  <snm>Livermore</snm>
                  <fnm>DM</fnm>
               </au>
               <au>
                  <snm>Brown</snm>
                  <fnm>DF</fnm>
               </au>
               <au>
                  <snm>Quinn</snm>
                  <fnm>JP</fnm>
               </au>
               <au>
                  <snm>Carmeli</snm>
                  <fnm>Y</fnm>
               </au>
               <au>
                  <snm>Paterson</snm>
                  <fnm>DL</fnm>
               </au>
               <au>
                  <snm>Yu</snm>
                  <fnm>VL</fnm>
               </au>
            </aug>
            <source>Clin Microbiol Infect</source>
            <pubdate>2004</pubdate>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <lpage>5</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1111/j.1469-0691.2004.00831.x</pubid>
                  <pubid idtype="pmpid" link="fulltext">14706093</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B23">
            <title>
               <p>Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation</p>
            </title>
            <aug>
               <au>
                  <snm>Goldstein</snm>
                  <fnm>FW</fnm>
               </au>
            </aug>
            <source>Clin Microbiol Infect</source>
            <pubdate>2002</pubdate>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>823</fpage>
            <lpage>5</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1046/j.1469-0691.2002.00492.x</pubid>
                  <pubid idtype="pmpid" link="fulltext">12519358</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B24">
            <title>
               <p>Purification and mutant analysis of <it>Citrobacter freundii </it>AmpR, the regulator for chromosomal AmpC beta-lactamase</p>
            </title>
            <aug>
               <au>
                  <snm>Bartowsky</snm>
                  <fnm>E</fnm>
               </au>
               <au>
                  <snm>Normark</snm>
                  <fnm>S</fnm>
               </au>
            </aug>
            <source>Mol Microbiol</source>
            <pubdate>1991</pubdate>
            <volume>5</volume>
            <fpage>1715</fpage>
            <lpage>25</lpage>
            <xrefbib>
               <pubid idtype="pmpid">1943705</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B25">
            <title>
               <p>Signalling proteins in enterobacterial AmpC beta-lactamase regulation</p>
            </title>
            <aug>
               <au>
                  <snm>Lindquist</snm>
                  <fnm>S</fnm>
               </au>
               <au>
                  <snm>Galleni</snm>
                  <fnm>M</fnm>
               </au>
               <au>
                  <snm>Lindberg</snm>
                  <fnm>F</fnm>
               </au>
               <au>
                  <snm>Normark</snm>
                  <fnm>S</fnm>
               </au>
            </aug>
            <source>Mol Microbiol</source>
            <pubdate>1989</pubdate>
            <volume>3</volume>
            <fpage>1091</fpage>
            <lpage>102</lpage>
            <xrefbib>
               <pubid idtype="pmpid">2691840</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B26">
            <title>
               <p>Analyses of <it>ampC </it>gene expression in <it>Serratia marcescens </it>reveal new regulatory properties</p>
            </title>
            <aug>
               <au>
                  <snm>Mahlen</snm>
                  <fnm>SD</fnm>
               </au>
               <au>
                  <snm>Morrow</snm>
                  <fnm>SS</fnm>
               </au>
               <au>
                  <snm>Abdalhamid</snm>
                  <fnm>B</fnm>
               </au>
               <au>
                  <snm>Hanson</snm>
                  <fnm>ND</fnm>
               </au>
            </aug>
            <source>J Antimicrob Chemother</source>
            <pubdate>2003</pubdate>
            <volume>51</volume>
            <fpage>791</fpage>
            <lpage>802</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1093/jac/dkg133</pubid>
                  <pubid idtype="pmpid" link="fulltext">12654751</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B27">
            <title>
               <p>Cloning, sequence analyses, expression, and distribution of <it>ampC-ampR </it>from <it>Morganella morganii </it>clinical isolates</p>
            </title>
            <aug>
               <au>
                  <snm>Poirel</snm>
                  <fnm>L</fnm>
               </au>
               <au>
                  <snm>Guibert</snm>
                  <fnm>M</fnm>
               </au>
               <au>
                  <snm>Girlich</snm>
                  <fnm>D</fnm>
               </au>
               <au>
                  <snm>Naas</snm>
                  <fnm>T</fnm>
               </au>
               <au>
                  <snm>Nordmann</snm>
                  <fnm>P</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>1999</pubdate>
            <volume>43</volume>
            <fpage>769</fpage>
            <lpage>76</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">10103179</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B28">
            <title>
               <p>Antibiotic resistance</p>
            </title>
            <aug>
               <au>
                  <snm>Murray</snm>
                  <fnm>BE</fnm>
               </au>
            </aug>
            <source>Adv Intern Med</source>
            <pubdate>1997</pubdate>
            <volume>42</volume>
            <fpage>339</fpage>
            <lpage>67</lpage>
            <xrefbib>
               <pubid idtype="pmpid">9048124</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B29">
            <title>
               <p><it>ampR </it>gene mutations that greatly increase class C beta-lactamase activity in <it>Enterobacter cloacae</it></p>
            </title>
            <aug>
               <au>
                  <snm>Kuga</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Okamoto</snm>
                  <fnm>R</fnm>
               </au>
               <au>
                  <snm>Inoue</snm>
                  <fnm>M</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>2000</pubdate>
            <volume>44</volume>
            <fpage>561</fpage>
            <lpage>7</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1128/AAC.44.3.561-567.2000</pubid>
                  <pubid idtype="pmpid" link="fulltext">10681318</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B30">
            <title>
               <p>MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections</p>
            </title>
            <aug>
               <au>
                  <snm>Pfaller</snm>
                  <fnm>MA</fnm>
               </au>
               <au>
                  <snm>Jones</snm>
                  <fnm>RN</fnm>
               </au>
            </aug>
            <source>J Antimicrob Chemother</source>
            <pubdate>2000</pubdate>
            <volume>46</volume>
            <issue>Suppl B</issue>
            <fpage>25</fpage>
            <lpage>37</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1093/jac/46.suppl_2.25</pubid>
                  <pubid idtype="pmpid" link="fulltext">10969060</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B31">
            <title>
               <p>Detection of <it>ampC </it>in <it>Enterobacter cloacae </it>in China</p>
            </title>
            <aug>
               <au>
                  <snm>Zhang</snm>
                  <fnm>YL</fnm>
               </au>
               <au>
                  <snm>Li</snm>
                  <fnm>JT</fnm>
               </au>
               <au>
                  <snm>Zhao</snm>
                  <fnm>MW</fnm>
               </au>
            </aug>
            <source>Int J Antimicrob Agents</source>
            <pubdate>2001</pubdate>
            <volume>18</volume>
            <fpage>365</fpage>
            <lpage>71</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0924-8579(01)00414-9</pubid>
                  <pubid idtype="pmpid" link="fulltext">11691570</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B32">
            <title>
               <p>Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant <it>Enterobacter aerogenes</it></p>
            </title>
            <aug>
               <au>
                  <snm>Charrel</snm>
                  <fnm>RN</fnm>
               </au>
               <au>
                  <snm>Pages</snm>
                  <fnm>JM</fnm>
               </au>
               <au>
                  <snm>De Micco</snm>
                  <fnm>P</fnm>
               </au>
               <au>
                  <snm>Mallea</snm>
                  <fnm>M</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>1996</pubdate>
            <volume>40</volume>
            <fpage>2854</fpage>
            <lpage>8</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">9124854</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B33">
            <title>
               <p>Porin alteration and active efflux: two in vivo drug resistance strategies used by <it>Enterobacter aerogenes</it></p>
            </title>
            <aug>
               <au>
                  <snm>Mallea</snm>
                  <fnm>M</fnm>
               </au>
               <au>
                  <snm>Chevalier</snm>
                  <fnm>J</fnm>
               </au>
               <au>
                  <snm>Bornet</snm>
                  <fnm>C</fnm>
               </au>
               <au>
                  <snm>Eyraud</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Davin-Regli</snm>
                  <fnm>A</fnm>
               </au>
               <au>
                  <snm>Bollet</snm>
                  <fnm>C</fnm>
               </au>
               <au>
                  <snm>Pages</snm>
                  <fnm>JM</fnm>
               </au>
            </aug>
            <source>Microbiology</source>
            <pubdate>1998</pubdate>
            <volume>144</volume>
            <fpage>3003</fpage>
            <lpage>9</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">9846735</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B34">
            <title>
               <p>Combination antibiotic therapy versus monotherapy for gram-negative bacteremia: a commentary</p>
            </title>
            <aug>
               <au>
                  <snm>Chow</snm>
                  <fnm>JW</fnm>
               </au>
               <au>
                  <snm>Yu</snm>
                  <fnm>VL</fnm>
               </au>
            </aug>
            <source>Int J Antimicrob Agents</source>
            <pubdate>1999</pubdate>
            <volume>11</volume>
            <fpage>7</fpage>
            <lpage>12</lpage>
            <xrefbib>
               <pubidlist>
                  <pubid idtype="doi">10.1016/S0924-8579(98)00060-0</pubid>
                  <pubid idtype="pmpid" link="fulltext">10075272</pubid>
               </pubidlist>
            </xrefbib>
         </bibl>
         <bibl id="B35">
            <title>
               <p>A functional classification scheme for beta-lactamases and its correlation with molecular structure</p>
            </title>
            <aug>
               <au>
                  <snm>Bush</snm>
                  <fnm>K</fnm>
               </au>
               <au>
                  <snm>Jacoby</snm>
                  <fnm>GA</fnm>
               </au>
               <au>
                  <snm>Medeiros</snm>
                  <fnm>AA</fnm>
               </au>
            </aug>
            <source>Antimicrob Agents Chemother</source>
            <pubdate>1995</pubdate>
            <volume>39</volume>
            <fpage>1211</fpage>
            <lpage>33</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">7574506</pubid>
            </xrefbib>
         </bibl>
         <bibl id="B36">
            <title>
               <p>Occurrence and detection of extended-spectrum beta-lactamases in members of the family <it>Enterobacteriaceae </it>at a veteran's medical center: seek and you may find</p>
            </title>
            <aug>
               <au>
                  <snm>Coudron</snm>
                  <fnm>PE</fnm>
               </au>
               <au>
                  <snm>Moland</snm>
                  <fnm>ES</fnm>
               </au>
               <au>
                  <snm>Sanders</snm>
                  <fnm>CC</fnm>
               </au>
            </aug>
            <source>J Clin Microbiol</source>
            <pubdate>1997</pubdate>
            <volume>35</volume>
            <fpage>2593</fpage>
            <lpage>7</lpage>
            <xrefbib>
               <pubid idtype="pmpid" link="fulltext">9316913</pubid>
            </xrefbib>
         </bibl>
      </refgrp>
   </bm>
</art>
